During the corresponding time, Myriad Genetics Inc saw a revenue deteriorated by -10.39 % year on year, sequentially revenue fell by -4.46 %. While revenue at the Myriad Genetics Inc 's corporate clients
Myriad Genetics Inc's Comment on Sales, Marketing and Customers
Myriad operates in the Cancer Care Continuum market, specializing in DNA-based diagnostic testing for eleven common cancer types, including breast, ovarian, colorectal, prostate, lung, and skin cancers. The company also serves the Prenatal Health and Mental Health markets. Myriad offers cancer therapy selection tests such as the Homologous Recombination Deficiency (HRD) test and is developing comprehensive genomic profiling tests. It provides the Precise MRD test for molecular residual disease detection, identifying this area as a growth opportunity. Myriad supports community medicine and biopharma partners with services including biomarker identification, companion diagnostic test development, regulatory registration, and commercialization. Strategic collaborations include partnerships with PATHOMIQ, Inc. for AI-driven prostate cancer diagnostics and SOPHiA GENETICS S.A. for a global liquid biopsy companion diagnostic solution. The company invests in clinical evidence development and product innovation to expand its markets and enhance patient and provider experiences.
Myriad Genetics, Inc. continues to make significant strides in the field of molecular diagnostics and precision medicine, successfully translating cutting-edge research into clinical practice. Recently, a groundbreaking study highlighting the performance of Myriad Genetics molecular residual disease (MRD) test, Precise MRD, was published in The Lancet Oncology. This publication represents another milestone in the company s mission to revolutionize cancer care, particularly for patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). Pioneering Precision with Precise MRD In the rapidly evolving landscape of oncology, the capacity to accurately detect and monitor residual disease is crucial for ...
Myriad Genetics: Unveiling Clinical Validity of Precise MRD at AACR Annual MeetingIn an era where precision medicine is increasingly guiding therapeutic decisions, Myriad Genetics continues to make impressive strides. The company recently highlighted the clinical validity of its molecular residual disease (MRD) testing platform, Precise MRD™, during a pivotal podium presentation at the annual meeting of the American Association for Cancer Research (AACR). This presentation underscored the transformative potential of Precise MRD™ in oncology, offering a glimpse into the future of cancer management. The Unmet Need Addressed by MRD TestingResidual disease in cancer patients poses substantial challenges in ...
In an evolving landscape of prostate cancer diagnostics and treatment, Myriad Genetics Prolaris test stands out as a significant advancement, recently classified as an advanced tool by the National Comprehensive Cancer Network (NCCN) in their Prostate Cancer Guidelines. This endorsement from such a prestigious and authoritative body underscores the transformative potential of genetic testing in personalizing patient care and improving prognostic accuracy. As prostate cancer continues to be one of the most commonly diagnosed malignancies among men, such advancements are essential for timely and effective clinical decision-making. The Rising Prevalence of Prostate CancerProstate cancer affects millions annual...
Myriad Genetics, Inc., a renowned leader in genetic testing and precision medicine, has recently unveiled a breakthrough study published in Genetics in Medicine. This study validates RiskScore, an innovative breast cancer risk assessment tool embedded within Myriad s MyRisk Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the widely used Tyrer-Cuzick model, making it a highly reliable and comprehensive breast cancer risk assessment calculator.Enhancing Breast Cancer Risk Assessment with RiskScore:Breast cancer is a prevalent global health concern affecting millions of women each year. Accurate and reliable risk assessment tools are crucial for early de...
QIAGEN and Myriad Genetics Collaborate to Develop Distributable Homologous Recombination Deficiency Test for Precision Medicine ResearchQIAGEN, a leading provider of molecular diagnostics solutions, and Myriad Genetics, a global leader in genetic testing and precision medicine, have announced their partnership to develop a kit-based test for the analysis of Homologous Recombination Deficiency (HRD) status. This groundbreaking next-generation sequencing (NGS) test aims to revolutionize personalized medicine research in various solid tumor types, particularly in ovarian cancer.The HRD test will enable researchers and clinicians to assess the efficacy of targeted therapy options and treatment strategies for pa...
Myriad Genetics Inc’s Comment on Sales, Marketing and Customers
Myriad operates in the Cancer Care Continuum market, specializing in DNA-based diagnostic testing for eleven common cancer types, including breast, ovarian, colorectal, prostate, lung, and skin cancers. The company also serves the Prenatal Health and Mental Health markets. Myriad offers cancer therapy selection tests such as the Homologous Recombination Deficiency (HRD) test and is developing comprehensive genomic profiling tests. It provides the Precise MRD test for molecular residual disease detection, identifying this area as a growth opportunity. Myriad supports community medicine and biopharma partners with services including biomarker identification, companion diagnostic test development, regulatory registration, and commercialization. Strategic collaborations include partnerships with PATHOMIQ, Inc. for AI-driven prostate cancer diagnostics and SOPHiA GENETICS S.A. for a global liquid biopsy companion diagnostic solution. The company invests in clinical evidence development and product innovation to expand its markets and enhance patient and provider experiences.
Sources:
Myriad Genetics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Myriad Genetics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Myriad Genetics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
122.86 %